Aveta Biomics
Aveta Biomics is a United States-based biotechnology company running 2 late-stage cancer trials of APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma.
Overview
Aveta Biomics, based in Bedford, the United States, is a biotechnology company. Aveta Biomics develops oral immunotherapies for cancer that apply principles of evolutionary biology to reprogram the tumour-immune ecosystem upstream of checkpoint pathways. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma. The largest, NCT06011109 (Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyQBiotics
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyRakuten Medical
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyAP Biosciences
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyHangzhou Hanx Biopharmaceuticals
Shares Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyTiumBio
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyNeonc Technologies
Shares Glioma & glioblastoma, Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyEpicentRx
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyPhilogen S.p.A.
Shares Glioma & glioblastoma and the tag ctgov-sponsor.